Tevogen Expands COVID-19 T Cell Therapy Reach With Multi-HLA Targeting, Expanding Patient Eligibility

Author: Benzinga Newsdesk | November 05, 2025 03:22pm

• This milestone expands patient eligibility through multi-HLA targeting
• Builds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patients
• TVGN 489 utilizes off-the-shelf, genetically unmodified allogeneic T cells
• TVGN 489 is designed to address both acute COVID-19 infection and Long COVID

WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced a clinical milestone in the evolution of its proprietary ExacTcell™ platform: completion of T cell target identification for an additional five human leukocyte antigen (HLA) restrictions. This advancement significantly broadens the accessibility of Tevogen's investigational precision T cell therapies by extending therapeutic reach beyond the single HLA-A*02:01 restriction used in the Company's initial proof-of-concept (POC) clinical trial, the results of which were published in Blood Advances. That study demonstrated the safety and feasibility of Tevogen's third-party cytotoxic T lymphocyte (CTL) therapy, TVGN 489, in high-risk patients with COVID-19.

HLA type varies widely among individuals and population groups. HLA-A*02:01 was selected for the proof-of-concept trial because it is one of the most common HLA types in the United States, present in approximately 25% of the population. Collectively, the identification of five additional HLA targets will allow the manufacture of CTLs which would extend treatment to approximately 65% of the US population, bolstering coverage for minority populations with less common HLA types.

Posted In: TVGN